Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123312 | 1.00 | GAA (0.42) | GAAL3MBTL1TDP1ALDH1A1LMNA | |
| SCHEMBL12270022 | 0.83 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1LMNAMAPTNPSR1 | |
| SCHEMBL31431068 | 0.82 | MAPT (0.38) | L3MBTL1ALDH1A1LMNAMAPTMET | |
| SCHEMBL25340072 | 0.81 | MAPT (0.37) | GAAL3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL18487086 | 0.79 | L3MBTL1 (0.45) | L3MBTL1NOTUMHSP90AA1AKT1BRD4 | |
| SCHEMBL3836430 | 0.79 | L3MBTL1 (0.45) | L3MBTL1NOTUMHSP90AA1AKT1BRD4 | |
| SCHEMBL424580 | 0.79 | L3MBTL1 (0.48) | L3MBTL1NOTUMHSP90AA1AKT1BRD4 | |
| SCHEMBL21054987 | 0.79 | ACLY (0.44) | L3MBTL1TDP1ALDH1A1LMNAMAPT | |
| SCHEMBL28299075 | 0.79 | KMT2A (0.45) | GAATDP1ALDH1A1METHSP90AA1 | |
| SCHEMBL3697440 | 0.79 | BRD4 (0.37) | L3MBTL1ALDH1A1LMNAMETHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| CN-118946553-A | SARM1 inhibitor compound, pharmaceutical composition comprising the same, and preparation method and use thereof | 深圳众格生物科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2023193809-A1 | SARM1 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USES THEREOF | 深圳众格生物科技有限公司 | 2023-10-12 | — | — | WO | disclosed |
| CN-116731045-A | KRAS inhibitor, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-113727972-A | Novel hydrazone derivatives in which terminal amino group is substituted with aryl or heteroaryl group, and use thereof | 韩国科学技术研究院 | 2021-11-30 | — | — | CN | disclosed |
| WO-2020130214-A1 | NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF | 한국과학기술연구원 | 2020-06-25 | — | — | WO | disclosed |
| US-20100036123-A1 | PROCESS FOR THE PREPARATION OF 2,4-DICHLORO-7H-PYRROLO[2,3H]QUINAZOLINE | WYETH (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100036123-A1 | PROCESS FOR THE PREPARATION OF 2,4-DICHLORO-7H-PYRROLO[2,3H]QUINAZOLINE | WYETH (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2009111547-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036123-A1 | PROCESS FOR THE PREPARATION OF 2,4-DICHLORO-7H-PYRROLO[2,3H]QUINAZOLINE | NQO2, QDPR, DHPS | GAA 1830/4885L3MBTL1 4843/4885TDP1 1725/4885 |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | MTOR, RICTOR, RPS6KA3 | GAA 3471/4885L3MBTL1 3081/4885TDP1 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.